Related Experiment Video
Updated: Jun 17, 2026
09:38
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Multiple sclerosis pharmacogenomics: maximizing efficacy of therapy
Neurology
|December 30, 2009
Summary
Pharmacogenomic studies can identify genetic markers to predict how individuals with multiple sclerosis will respond to treatments. This research aims to personalize therapy by analyzing genetic variations and clinical outcomes.
Area of Science:
- Pharmacogenomics
- Neuroimmunology
- Clinical Pharmacology
Background:
- Interindividual variability in drug response is influenced by genetic factors affecting drug targets and metabolism.
- Multiple sclerosis (MS) exhibits disease heterogeneity and varied responses to disease-modifying therapies, necessitating personalized treatment strategies.
- Current therapeutic approaches for MS lack reliable biomarkers for predicting individual treatment efficacy and toxicity.
Purpose of the Study:
- To define predictive biomarkers for therapeutic response in multiple sclerosis through pharmacogenomic analysis.
- To correlate specific genomic variants with clinical outcomes in patients undergoing treatment for MS.
- To address the heterogeneity of MS pathology and treatment response by investigating genetic influences.
Main Methods:
- Conducting pharmacogenomic studies with longitudinal designs to track treatment responses over time.
- Utilizing whole-genome technologies to comprehensively analyze genetic variations within large patient cohorts.
- Developing novel mathematical algorithms to integrate diverse datasets and identify subtle genetic effects and interactions.
Main Results:
- Analysis of correlations between genomic variants and clinical responses to MS therapies is ongoing.
- Identification of potential genetic biomarkers that may predict therapeutic response in MS patients.
- The study design facilitates the detection of modest genetic effects and complex gene-gene interactions.
Conclusions:
- Pharmacogenomic studies are crucial for understanding and overcoming interindividual variability in MS treatment.
- Identifying genetic biomarkers will enable a priori prediction of therapeutic response and optimization of MS treatment regimens.
- Personalized medicine approaches in MS can be advanced through the integration of genomic data and clinical outcomes.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...